About Embla Medical

Sveinn Sölvason, President and CEO, comments:

“We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025. 

Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. The EBITDA margin came in at 19% compared to 21% in Q4 2024. The margin was positively impacted by strong sales growth and manufacturing efficiency but negatively impacted by FX, tariffs, and initiatives to enhance long-term growth and profitability in our Patient Care segment."

Embla Medical will host a conference call on February 3, 2026, at 9:00 CET / 7:00 GMT / 3:00 ET. Please visit our Investor Relations section for further information.

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.